A Phase I, Gene Alteration-based, Open Label, Multicenter Study of Oral Debio 1347 (CH5183284) in Patients With Advanced Solid Malignancies, Whose Tumours Have an Alteration of the FGFR 1, 2 or 3 Genes

Trial Profile

A Phase I, Gene Alteration-based, Open Label, Multicenter Study of Oral Debio 1347 (CH5183284) in Patients With Advanced Solid Malignancies, Whose Tumours Have an Alteration of the FGFR 1, 2 or 3 Genes

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Debio 1347 (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Small cell lung cancer; Solid tumours; Uterine cancer
  • Focus Adverse reactions; First in man
  • Sponsors Debiopharm Group
  • Most Recent Events

    • 24 Jul 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Sep 2017.
    • 15 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 Jun 2017 Results (n=56) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top